Why advanced knee OA sometimes needs two injections

Most advanced knee pain has two sources running in parallel, and treating only one of them is a common reason injections produce relief that fades or never quite reaches the level patients hoped for. Cartilage that has worn through generates aching, load-dependent pain — the kind that bites on stairs, first thing in the morning, or after sitting for any length of time. A separate but simultaneous problem is synovial inflammation: the joint lining becomes reactive, producing swelling, heat, and unpredictable flares that can strike even at rest.

A single injection aimed at one target leaves the other entirely intact. The CFI+ protocol addresses this by pairing two agents in a single outpatient appointment — no surgery, no general anaesthetic, no theatre admission. ChondroFiller, a sterile collagen scaffold, is placed onto the worn cartilage surface at the bone ends; Arthrosamid, a 2.5% polyacrylamide hydrogel, is delivered into the synovial membrane lining. They act through fundamentally different mechanisms and should not be thought of as two doses of the same treatment — each is doing a different job at a different anatomical address within the same joint.

How ChondroFiller and Arthrosamid each work

The two products work through entirely different biological processes, and understanding those differences matters for setting realistic expectations about what improves and when.

ChondroFiller is a 2.3 mL sterile type I collagen scaffold. Under ultrasound guidance, it is placed directly onto the worn cartilage surface at the load-bearing bone ends — the site of mechanical damage. Once in position, it acts through acellular matrix-induced chondrogenesis: the scaffold creates a structured environment that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone. Those cells migrate into the matrix and begin laying down new cartilage-like tissue. This is an active, biologically driven process, and it unfolds gradually — meaningful tissue remodelling typically occurs over six to twelve months rather than days or weeks.

Arthrosamid is a 6 mL injection of 2.5% polyacrylamide hydrogel. It is delivered into the synovial membrane lining rather than the cartilage surface itself, where it integrates with the tissue and provides lasting mechanical cushioning from within the joint wall. Its role is structural and anti-inflammatory — calming the reactive synovial environment that drives swelling, heat, and unpredictable flares. It does not promote endogenous repair or rebuild lost cartilage tissue; that is not its function.

Both injections are delivered in the same outpatient appointment using ultrasound-guided placement, with no surgery or general anaesthetic involved. Because each agent targets a distinct anatomical structure — cartilage surface versus synovial lining — and operates through a different mechanism, the timelines for effect also differ: Arthrosamid's cushioning and anti-inflammatory action tends to be felt sooner, while ChondroFiller's regenerative contribution develops over the months that follow.

Who the protocol suits — and what rules it out

Candidacy for CFI+ rests on two converging findings: visible cartilage loss on MRI — typically Kellgren-Lawrence Grade III or IV — and a joint that is also reactive. That second criterion matters more than it might appear. A reactive joint is one that swells and settles in cycles, aches at rest or overnight, or flares disproportionately after activity. Patients often describe it as the joint having a mind of its own — good weeks and bad weeks with no clear trigger. When both features are present simultaneously, the two injections have something concrete to act on at each of their separate targets.

Age is not a barrier. ChondroFiller's scaffold can be applied across the entire articular surface in a single session, so diffuse or widespread wear — the kind that rules out focal surgical techniques — does not preclude the protocol. Patients in their 60s, 70s, and beyond who wish to preserve the joint and defer or avoid total knee replacement are among those for whom CFI+ is most commonly considered.

What the protocol does require is a structurally stable joint. Untreated ligament instability, significant malalignment, or a meniscal deficit that is actively driving the wear pattern each need to be addressed before ChondroFiller can be placed effectively — introducing a scaffold into a mechanically compromised joint reduces the conditions needed for it to work.

For a smaller subset of patients with more extreme structural destruction, or where comorbidities such as diabetes may attenuate outcomes — cohort data suggest non-diabetic status independently predicts better functional response to polyacrylamide hydrogel — a further escalation exists. The Tri-Active Therapy adds autologous mesenchymal stem cells to the CFI+ combination (priced at £11,000), providing cellular signalling alongside scaffold regeneration and synovial cushioning. This represents a higher-tier option for the most challenging presentations, not a signal that the dual protocol has fallen short.

What the clinical evidence shows

Published data for the two components sit at different levels of maturity, and it is worth being explicit about that asymmetry from the outset.

Arthrosamid

A 2025 five-year prospective extension study (n=49 enrolled; 27 completers) reported statistically significant and sustained improvements in WOMAC pain (−14.6; p=0.0002), stiffness (−19.6; p=0.0006), and physical function (−12.5; p=0.0015) following a single 6 mL intra-articular injection, with no serious device-related adverse events across the entire follow-up period. A separate 2025 retrospective comparative study found iPAAG outperformed corticosteroid on VAS at six months (p<0.001) and on WOMAC (p=0.008), and remained stable at twelve months while both the hyaluronic acid and corticosteroid groups had returned to near-baseline scores.

ChondroFiller

Published outcome anchors for ChondroFiller as an injectable scaffold include approximately 30-point IKDC improvement in the knee, MOCART scores in the 70–87 range, and a complaint rate of approximately 0.06%. These figures support clinical use; however, the injectable-scaffold evidence base is smaller in volume than the registry and cohort data now available for polyacrylamide hydrogel. Arthrosamid has a larger published cohort registry — that asymmetry is real and should inform how patients weigh each component.

The combination

No published randomised controlled trial has evaluated the CFI+ protocol against either agent given alone. The additive benefit is grounded in mechanistic rationale — each product acts on a distinct anatomical target — alongside clinical practice experience, not controlled trial data. Patients considering this protocol should factor that gap into their decision alongside the individual component evidence summarised above.

What happens after the injection and how long effects last

The two components operate on different clocks, and understanding that distinction before the appointment matters more than it might seem.

Arthrosamid, as a structural hydrogel, integrates with the synovial lining relatively quickly. Patients often notice a reduction in the reactive, aching quality of the joint — fewer overnight flares, less swelling after activity — within the first weeks to a few months. That early relief is genuine, but it reflects cushioning and anti-inflammatory modulation at the synovial wall rather than any change at the cartilage surface. The five-year cohort data discussed in the previous section confirm this effect holds without regression across the full follow-up period; durability is one of the hydrogel's defining clinical attributes.

ChondroFiller's repair is a slower biological process. The patient's own progenitor cells must migrate into the collagen scaffold and begin depositing new matrix — a process that typically unfolds over six to twelve months. That differential creates a practical risk for self-assessment: a patient who feels substantially better at eight or ten weeks is most likely responding to Arthrosamid's cushioning effect. Interpreting that improvement as evidence that cartilage repair is complete would be premature, because scaffold integration continues well beyond the point of initial symptom relief.

Understood together, the two timelines are additive rather than competing. Arthrosamid addresses load comfort and joint reactivity in the short-to-medium term; ChondroFiller continues its repair process in the background. A review consultation around the twelve-month mark — typically including imaging — allows assessment of scaffold integration and informs any further decisions about the joint.

Getting assessed for the protocol at LCC

For patients weighing this up honestly, the protocol makes most sense when both pain generators are confirmed — cartilage loss on MRI and a joint that is also reliably reactive — and when total knee replacement is either premature or genuinely unwanted. The Arthrosamid component carries the stronger published evidence base at five years; ChondroFiller's injectable-scaffold data are encouraging but smaller in volume, and no controlled trial has tested the combination directly. That gap does not disqualify the protocol, but it does suggest that patients with predominantly structural problems, mild synovial involvement, or poorly controlled comorbidities such as diabetes may find more predictable value in a single-agent approach or in addressing those factors first.

Where the dual indication is confirmed, assessment at LCC's Harley Street clinic brings MRI findings, structural stability, and the patient's symptom pattern together rather than treating each in isolation. Professor Paul Y. F. Lee, who leads cartilage preservation work at the clinic, carries out this candidacy evaluation. A consultation to explore whether the protocol fits a particular presentation can be requested via londoncartilage.com.

1. [1] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655
2. [2] A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection in participants with knee osteoarthritis: a 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0